Navigation Links
WorldHeart Announces Possible Delisting Action by NASDAQ
Date:5/15/2008

), as required by Marketplace Rule 4310(c)(7) for continued listing on the NASDAQ Capital Market. As of May 9, 2008, the MVPHS of the Company totaled $857,242.

If the Company does not appeal Staff's determination to the Panel, the Company's securities will not be immediately eligible to trade on the OTC Bulletin Board or in the "Pink Sheets." The securities may become eligible if a market maker makes application to register in and quote the security in accordance with SEC Rule 15c2-11, and such application (a "Form 211") is cleared. Only a market maker, not the Company, may file a Form 211.

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems. The Company is headquartered in Oakland, California, USA with additional facilities in Salt Lake City, Utah and Herkenbosch, Netherlands. WorldHeart's registered office is Ottawa, Ontario, Canada.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include any statements regarding the Company's ability to regain compliance with the NASDAQ Capital Market listing requirements, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: the Company's immediate need for additional capital, risks in product development and market acceptance of and demand for the Company's products; delisting from the NASDAQ Stock Market if compliance with the listing standards, including the Minimum Bid Price Rule and other minimum standards, is not regained; and other risks detailed in the Corporation's filings with the U.S. Securities and
'/>"/>

SOURCE World Heart Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. WorldHeart Notified of TSX Delisting Review
2. WorldHeart Appoints David Pellone Chief Financial Officer
3. Mergent, Inc. Announces Changes to the HealthShares(TM) Composite Index, Dermatology and Wound Care Index and Orthopedic Repair Index - Correction
4. Perot Systems Announces the Launch of Xcelys(TM) 5.0 Software
5. Duane Reade Announces Proud Sponsorship of AIDS Walk New York
6. Summit VetPharm Announces Grand Prize and March Winner in its Great Vectra 3D(TM) $125,000 Giveaway
7. The Canary Foundation Announces Its Fourth Annual Early Detection Symposium
8. Sharps Compliance Corp. Announces Results for Third Quarter of Fiscal Year 2008
9. Human Pheromone Sciences Announces First Quarter Results
10. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
11. The Quantum Group Announces Web-Based Portal for Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
... old was declared brain dead in a hospital in Hyde... the organs of their loved one. // MOHAN (Multi Or...s were called in and they provided the family with...s were being undertaken. It was late evening befor...
...e men hailing from the Dudu Town of India’s Rajast...high fluoride content in its water. The excessive ...lems in the people living in the area.// 'I have ... efforts to find brides for them have failed due t...
...ty reducing drugs are awaiting FDA approval and if...tures with high profits due to sales of these drug...al regulators before it could be available as a co...are the two new anti-obesity drugs and could help ...
...tion is reported in two Chinese province of Ningxi... to threaten Asia which is already facing outbreak...umans is rare // but they cause immense economic l...burden of the farmers who are already facing loss ...
Other Medicine News:Health News:A first in Liver Transplant in India – Networking works wel 2Health News:Polluted Water Prevents Men From Getting Married 2
(Date:9/4/2008)...mg cohort demonstrates potent antiviral activity a...profile -, CAMBRIDGE, Mass., Sept. 4 /PRNewswire-...: IDIX ), a biopharmaceutical company engaged,in ...atment of human viral,and other infectious disease...-of-concept study evaluating IDX899, a non-nucleos...
(Date:9/3/2008)...NJING, China, Sept. 3 /- Si...g manufacturer and supplier of,branded generic pha...-cancer biotech product Endu (also known as Endost...u Phase IV clinical study., At the request of the...,to further validate the safety and therapeutic ef...
(Date:9/3/2008)...ITHERSBURG, Md., Sept. 3 /- Panacea P...of U.S. Patent Number 7,413,737 covering,antibodie...ylase (HAAH), a,proprietary human cancer biomarker...eloped in collaboration with the Massachusetts Ins...ve, worldwide rights to this patent,for developmen...
(Date:9/3/2008)...B-509 to be Evaluated in Repeat-Dosing Study in Su...swire-FirstCall/ -- Sangamo,BioSciences, Inc. (Nas...Phase,2 clinical trial (SB-509-801) to evaluate it...e, degenerative motor-neuron disease for which the...ngamo,s drug, SB-509, is an injectable formulation...
Breaking Medicine Technology:Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Faster koa tree growth without adverse ecosystem effects 2641 1Faster koa tree growth without adverse ecosystem effects 2641 2Virginia Kids Kick Butts on April 2 15289 1Virginia Kids Kick Butts on April 2 15289 2Virginia Kids Kick Butts on April 2 15289 3Florida Kids Kick Butts on April 2 15286 1Florida Kids Kick Butts on April 2 15286 2Florida Kids Kick Butts on April 2 15286 3Florida Kids Kick Butts on April 2 15286 4Bond Laboratories First Quarter Fiscal 2008 Sales Exceeding Internal Projections 15283 1Bond Laboratories First Quarter Fiscal 2008 Sales Exceeding Internal Projections 15283 2
...tralia, March 14, 2007 /Xinhua-PRNewswire-FirstCal...nced the results,from its Phase II trial for Arido...isease (COPD), a respiratory disease,affecting ove...ducted in 79 diagnosed COPD patients at 12,centres...was to,determine if subjects that were positive to...
...cipates second quarter BLA filing for C1-inhibitor...Newswire-FirstCall/ -- Lev,Pharmaceuticals, Inc. (...otal U.S. Phase III trial of C1-esterase inhibitor...gioedema (HAE). In the,acute study, which is part ...reditary Angioedema Nanofiltration Generation,eval...
Other Medicine Technology:Pharmaxis Reports Phase II Results for Aridol in COPD 2Pharmaxis Reports Phase II Results for Aridol in COPD 3Pharmaxis Reports Phase II Results for Aridol in COPD 4Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 2Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 3Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 4Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 5
...nd medium volume laboratories, as well as specialt...simplicity and flexibility needed to respond to mu... the Elecsys 1010 system enables operators to hand...e testing without sacrificing ease of operation or...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t
...stry System provides high-performance detection te...c proteins and therapeutic drugs. It also delivers...ow the laboratory to streamline its operations and...esign enables numerous functions to be performed s...
The Embla 384 cell washer is a top-loading, robotic-compatible microplate washer for high throughput screening. It is designed specifically for cell-based assays, which require a gentler wash, but ca
Medicine Products: